Article
ALERT: FDA slaps a hold on a star Regeneron cancer drug, pausing trial enrollment as cytokine storm
Rating:
0.0
Views:
126
Likes:
1
Library:
1
Less than two years after one of Regeneron's star cancer drugs was in the spotlight following the death of two patients from cytokine storms, it's back at center ring over fresh tox concerns. And this time, CRS has brewed back up to force a partial hold on further enrollment for
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value